Alzhimer disease
Conditions
Interventions
The patients began treatment with donepezil 3mg once a daily. The total daily dose was increased by 5mg day.
The patients began treatment with galantamine 4mg twice daily. The total daily dose was inc
Sponsors
Department of Neuropsychiatry, Keio University School of Medicine,
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A diagnosis of probable AD according to the National Institute of Neurological and Communication Disorders and Stroke Alzheimer Disease and Related Disorders Association criteria, very mild to mild , moderate functional severity, reliable informed consent could be obtained from the patient and or his her relatives, the chief caregiver is the patients family ,the patients Mini Mental State Examination score was less than 11
Exclusion criteria
Exclusion criteria: either previous history or now taking other choline inhibitors (galantamine, rivastigmine) and memantine, taking antipsychotic or antidepressant medication ,there was a previous history of mental llness or substance abuse,either an MRI or a CT scan had revealed focal brain lesions,routine blood tests (including evaluation of serum vitamin B12 and thyroid function) were abnormal findings , the patient has pacemaker, other findings in terms with the aims of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical assessment for spontaneity | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Cognitive assessment Mini-Mental State Examination (MMSE) Clock drawing test The Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog) Frontal assessment battery (FAB) 2 Behavior assessment Clinical assessment for spontaneity (CAS) Neuropsychiatry Inventory Questionnaire (NPI-Q) Quality of life-Alzheimer Disease (QOL-AD) Scale | — |
Countries
Japan
Contacts
Public ContactShutaro Nakaaki
Keio University School of Medicine Department of Neuropsychiatry, Laboratory of Aging, Behavior and Cognition
Outcome results
None listed